690257-74-0
690257-74-0
Chemical Structure
MK-0626
- CAS No.: 690257-74-0
- Formula:C22H24F2N6O2
- Molecular Weight:442.46
InChIKey: HOLMVLAGEPDFQK-OALUTQOASA-N
SMILES: O=C(N1CC(F)(CC1)F)[C@@H](N)[C@H](C2=CC=C(C3=CN4C(C=C3)=NC=N4)C=C2)C(N(C)C)=O
Biological Activity: MK-0626 is a selective, orally active DPP-4 inhibitor with an IC50 of 6.3 nM. MK-0626 increases endothelial nitric oxide synthetase expression. MK-0626 improves neovascularization, attenuates hepatic steatosis, attenuates pancreatic islet injury. MK-0626 can be used in the research of diabetes and non-alcoholic fatty liver disease[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MK-0626 | MK-0626 is a selective, orally active DPP-4 inhibitor with an IC50 of 6.3 nM. MK-0626 increases endothelial nitric oxide synthetase expression. MK-0626 improves neovascularization, attenuates hepatic steatosis, attenuates pancreatic islet injury. MK-0626 can be used in the research of diabetes and non-alcoholic fatty liver disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Shih CM, et al. MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression. Curr Med Chem. 2014 Jun;21(17):2012-22. [Content Brief]
- [2]. Ohyama T, et al. MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice. World J Gastroenterol. 2014 Nov 21;20(43):16227-35. [Content Brief]
- [3]. Jin L, et al. Dipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic rats. PLoS One. 2014 Jun 24;9(6):e100798. [Content Brief]
